Targeted Therapy Is Not a “Magic Bullet”: What Should Be Done When Resistance Occurs?

By:DengYue International Business Division

The development of targeted therapies has significantly transformed the treatment landscape for many driver gene–positive malignancies. In diseases such as EGFR-mutant non-small cell lung cancer (NSCLC), BCR-ABL–positive chronic myeloid leukemia (CML), and HER2-positive breast cancer, targeted treatments have not only prolonged survival but also substantially improved patients’ quality of life.

However, in real-world clinical practice, the efficacy of targeted therapies is not indefinite. Most patients eventually develop varying degrees of drug resistance after a period of treatment. Understanding the underlying mechanisms of resistance and formulating appropriate subsequent treatment strategies has therefore become a central challenge in precision oncology.

As a professional organization engaged in the global distribution and clinical support of innovative oncology drugs, Hong Kong DengYuemed has continuously monitored the mechanisms of resistance and corresponding therapeutic approaches throughout the clinical application and introduction of multiple targeted agents.

This article provides a systematic overview of the key mechanisms of resistance to targeted therapy and summarizes current standard and emerging strategies to address this challenge from a clinical and scientific perspective.

The Biological Basis of Resistance: Tumor Adaptive Evolution

Resistance to targeted therapy is generally classified into primary resistance and acquired resistance, with the latter being more common in clinical settings. Acquired resistance typically develops after months to years of treatment.

Biologically, resistance reflects the ability of tumor cells to adapt under drug selection pressure. Through genetic or epigenetic alterations, certain tumor cell populations gain a survival advantage and gradually expand into dominant clones.

According to recent consensus guidelines and studies, including those from ESMO and CSCO, resistance mechanisms can be broadly categorized as follows.

Major Mechanisms of Resistance

1. On-Target Resistance

Alterations in the drug target itself represent one of the most well-characterized resistance mechanisms. These changes can reduce or abolish drug binding affinity.

Representative examples include:

● EGFR mutation evolution from T790M to C797S (commonly associated with osimertinib resistance)

● ALK mutations such as G1202R and L1196M

● BCR-ABL mutation T315I

These alterations often necessitate the use of next-generation inhibitors specifically designed to overcome resistance.

2. Bypass Pathway Activation

Tumor cells may maintain proliferation and survival by activating alternative signaling pathways when the primary driver pathway is inhibited.

Common examples include:

● MET amplification in EGFR-mutant lung cancer (one of the most frequent bypass mechanisms, occurring in approximately 20–30% of cases)

● Activation of PI3K/AKT/mTOR or MAPK pathways in HER2-positive tumors

● Upregulation of KRAS/RAF/MEK signaling

This mechanism highlights the limitation of single-pathway inhibition in long-term disease control.

3. Downstream Activation and Phenotypic Transformation

In some cases, tumor cells undergo more complex biological changes, including:

● Epithelial–mesenchymal transition (EMT)

● Transformation from NSCLC to small cell lung cancer (SCLC), observed in approximately 5–15% of cases after EGFR-TKI resistance

● Histological shifts such as adenocarcinoma to squamous carcinoma

These changes may reduce tumor dependence on the original target, requiring a shift in therapeutic strategy.

4. Tumor Microenvironment and Non-Genetic Resistance

Non-genetic mechanisms also play a critical role in resistance, including:

● Overexpression of drug efflux pumps (e.g., ABCB1)

● Emergence of drug-tolerant persister (DTP) cells

● Metabolic reprogramming, such as increased reliance on oxidative phosphorylation

● Immune evasion and remodeling of the tumor microenvironment

These mechanisms are often dynamic and may coexist with genetic alterations, further complicating treatment.

In clinical practice, resistance is rarely driven by a single mechanism. Instead, multiple mechanisms often coexist or evolve sequentially. Therefore, comprehensive assessment is essential.

Currently, liquid biopsy (ctDNA) combined with tissue biopsy is considered the standard approach for evaluating resistance.

Treatment Strategies After Resistance: Current Approaches (2025–2026)

Treatment decisions after resistance should be based on resistance mechanisms, prior therapies, patient performance status, and drug accessibility. Current strategies can be summarized as mechanism-driven therapy, combination approaches, and next-generation agents.

1. Mechanism-Driven Next-Generation Targeted Therapy

When specific resistance mechanisms are identified, corresponding targeted strategies may be applied:

● EGFR C797S mutation: fourth-generation EGFR inhibitors (e.g., BLU-945, CH7233163, EAI-432; currently in clinical development)

● MET amplification: combination of osimertinib with MET inhibitors (such as cabozantinib, tepotinib, or savolitinib), with multiple real-world studies demonstrating improved progression-free survival

● ALK G1202R mutation: lorlatinib as a standard subsequent option

● BCR-ABL T315I mutation: ponatinib or asciminib

2. Local Therapy Combined with Systemic Treatment (Oligoprogression Strategy)

For patients with limited disease progression (typically ≤3–5 lesions), current guidelines recommend continuing the original targeted therapy in combination with local treatments such as radiotherapy, stereotactic body radiation therapy (SBRT), or ablation.

This approach has been shown to extend progression-free survival by an additional 6–18 months in selected patients.

3. Combination Therapy to Overcome Resistance

To address pathway redundancy and resistance, combination strategies are increasingly utilized:

● Targeted therapy plus targeted therapy (e.g., osimertinib combined with VEGF or MET inhibitors, or HER3 ADCs)

● Targeted therapy plus immunotherapy (e.g., EGFR-TKI combined with PD-1/PD-L1 inhibitors in selected populations)

● Targeted therapy plus chemotherapy, particularly in rapidly progressing disease

4. Emerging and Investigational Strategies

Several promising approaches are under active investigation:

● Next-generation antibody–drug conjugates (ADCs), such as HER3-DXd and TROP2-targeted agents

● Multi-target inhibitors and bispecific antibodies

● Metabolic-targeted therapies (e.g., IDH inhibitors, mitochondrial-targeting agents)

● AI-assisted resistance prediction and dynamic monitoring using ctDNA-based minimal residual disease (MRD)

● Intermittent dosing or dose modulation strategies to delay resistance onset

Clinical Management: The Importance of Precision Assessment

Accurate evaluation following resistance is critical for optimal treatment planning. Current clinical recommendations include:

● Performing ctDNA-based genomic profiling to identify resistance mechanisms

● Conducting tissue biopsy when feasible to assess histological transformation

● Utilizing a multidisciplinary team (MDT) approach for individualized treatment planning

● Prioritizing enrollment in appropriate clinical trials when available

In this context, drug accessibility and timely supply are also important factors influencing clinical decision-making.

Within a compliant regulatory framework, Hong Kong DengYue Pharmaceutical supports multiple healthcare institutions by providing access to a broad range of targeted therapies, including EGFR inhibitors, MET inhibitors, ALK inhibitors, and ADC agents. The company also facilitates clinical research and ensures a stable international supply chain to meet evolving treatment needs.

Conclusion

Resistance to targeted therapy represents an expected phase in the course of cancer treatment rather than a terminal point in therapeutic options. With a deeper understanding of resistance mechanisms and the continued development of next-generation therapies, resistance management is becoming increasingly precise and diversified.

Through dynamic monitoring, mechanism-based treatment selection, and rational combination strategies, it remains possible to prolong survival and improve clinical outcomes.

Looking ahead, the integration of multi-omics technologies, artificial intelligence, and novel drug platforms is expected to further enhance the controllability of resistance.

Hong Kong DengYue Pharmaceutical Co., Ltd. will continue to follow global advances in oncology and collaborate with leading pharmaceutical companies to support the delivery of innovative therapies to patients, contributing to the ongoing evolution of precision cancer care.